This site is intended for US patients only

Go to HCP Site

This site is intended for US patients only

Go to HCP Site
Join Patient Support Network

Severe Primary IGF-1 Deficiency Support and Information

Learn about the ETON CARES® support program and download the patient information booklet on starting and staying on treatment with INCRELEX® (mecasermin). You can also find links to useful online resources to help you when you start your INCRELEX® treatment journey.

Please see Indication and Important Safety Information below.

Olive, a former
Increlex patient,
at age 10.

Severe Primary IGF-1 Deficiency Support and Information

Learn about the ETON CARES® support program and download the patient information booklet on starting and staying on treatment with INCRELEX® (mecasermin). You can also find links to useful online resources to help you when you start your INCRELEX® (mecasermin) treatment journey.

Please see Indication and Important Safety Information below.

Learn

Online support

Online Support and Events

Eton Cares

Eton Cares provides copay and financial support. Patients who have been prescribed Increlex are automatically enrolled in Eton Cares.* Our reliable professionals are fully trained on Increlex and SPIGFD.

Copay Support

Eton Cares can help eligible, commercially insured patients get their medication for as little as $0 per month.*

Financial Support

Patients who do not have insurance and meet certain financial requirements may be eligible for additional financial support from a Patient Assistance Program.*

*Restrictions, limitations, and/or eligibility requirements may apply. For patients who are not eligible for copay support or who need additional financial assistance, Eton Cares can help connect you with alternative forms of medication coverage or provide referrals to other possible sources of funding.

Eton Cares

Eton Cares is a comprehensive support program designed to help patients get access to the medications and services that you need. The program is designed to simplify the process of applying for and getting coverage for INCRELEX® (mecasermin) as well as to serve as a central point of contact between you, your healthcare provider, insurance companies, and specialty pharmacies.

Patients prescribed INCRELEX® are automatically enrolled in Eton Cares. Through the program, eligible, commercially insured patients can receive their medication for a co-pay of $0.*

Patients also have access to a dedicated team of:

Insurance specialists

  • Assist with the insurance process, such as prior authorization and appeal support
  • Investigate insurance coverage for your medication
  • Help with co-pay assistance and other financial assistance options

Pharmacists

  • Answer all the questions needed about your medication
  • Provide refill reminders and ensure your medication arrives on time
  • 24/7/365 support

Nurse ambassadors

  • Check in with you to answer any questions you have about INCRELEX®

*Restrictions, limitations, and/or eligibility requirements apply.

The MAGIC Foundation

The MAGIC [Major Aspects of Growth In Children] Foundation for children’s growth is an American nonprofit organization. The Foundation helps families of children diagnosed with growth-impacting medical conditions through education, networking, and many other services.

The Human Growth Foundation

The Human Growth Foundation is an American nonprofit organization that is actively involved in patient advocacy, endocrine research, and provides family education and support on growth disorders and their treatment. The Foundation’s vision includes helping children with growth disorders and their healthcare providers by increasing awareness and the importance of early diagnosis and treatment.

International Children’s Growth Awareness Day

The International Children’s Growth Awareness Day is held on the 20th September every year and is when organizations around the world unite to promote and educate about the importance of annual growth checks for children. Growth Awareness Day is an initiative of the International Coalitions of Organizations Supporting Endocrine Patients (ICOSEP).

INCRELEX® Information

INCRELEX® (mecasermin) Information

Each Child is Unique – Patient Education Brochure

This brochure provides information about INCRELEX® for those who are starting their

IGF-1 treatment journey. It provides details of how INCRELEX® works to help children grow and how their treatment needs to be determined based on their age, weight, and height, among other factors, such as tolerability.

The brochure provides a practical means for you to record your child’s growth progress, and space to note any questions that you may wish to ask during follow-up appointments. Important safety information about INCRELEX® treatment is included, as is information about the Eton Cares support program.

Download

Tips on How to Give an Increlex® Injection

Important tips about administering Increlex

Download

What to Expect When Administering Increlex®

Some helpful information on the possible side effects of Increlex and ways to help manage them.

Download

Healthcare Provider Resources

Tips on How to Give an Increlex® Injection

Important tips about administering Increlex.

Download Now

What to Expect When Administering Increlex®

Some helpful information on the possible side effects of Increlex and ways to help manage them.

Download Now

INDICATION AND IMPORTANT SAFETY INFORMATION

INCRELEX® (mecasermin) is a prescription medicine used in children 2 years and older with short stature that have severely low levels of the hormone, insulin-like growth factor-1 (IGF-1). IGF-1 is needed for normal growth.

Increlex is not a substitute for growth hormone. It cannot be used for children with short stature due to low levels of growth hormone, malnutrition, when their thyroid gland doesn't make enough thyroid hormone, or when taking anti-inflammatory steroids used to manage inflammation.

IMPORTANT SAFETY INFORMATION

Always give Increlex exactly as your doctor directed.

Do not take INCRELEX if you are allergic to IGF-1 or any of its other ingredients. Report any allergic reactions.

INCRELEX should be injected under the skin and into the muscle. It should not be injected directly into a blood vessel.

INCRELEX should not be used after growth plates close which happens during puberty.

INCRELEX should not be used in children with cancerous tumors or a history of cancer.

  • Hypoglycemia (low blood sugar): INCRELEX should be administered 20 minutes before or after a meal or snack and should not be administered when the meal or snack is skipped. Checking blood glucose levels is recommended. The dose of INCRELEX may need to be adjusted until an appropriate dose is decided by your doctor.
  • Intracranial Hypertension: Increased pressure in your skull may occur because of cerebrospinal fluid buildup around your brain. Therefore, your doctor may require an eye examination at the start of Increlex treatment and periodically during the time you are taking INCRELEX.
  • Lymphoid Tissue Hypertrophy: Lymphoid tissue hypertrophy is a noncancerous increase in the number of immune cells called lymphocytes. Patients should have periodic examinations with your doctor to rule out potential complications.
  • Slipped Capital Femoral Epiphysis: Slipped capital femoral epiphysis is a bone problem where the top of the upper leg (femur) slips apart. This may lead to a serious condition where bone tissue dies due to a lack of blood supply (osteonecrosis). Get medical help for your child right away if your child develops a limp or has hip or knee pain.
  • Progression of Scoliosis: Your doctor will monitor you during treatment with INCRELEX if you have a history of scoliosis.
  • Malignant Neoplasia: There have been reports of cancerous tumors in children who received INCRELEX. It is unknown whether there is any relationship between INCRELEX therapy and new occurrence of tumors. Tumors were mostly reported in patients with rare genetic conditions of short stature associated with a higher risk of cancer, or in patients already at risk of cancer. The tumors were seen more frequently in patients who received INCRELEX at higher than recommended doses or at doses that produced IGF-1 levels above normal for age and sex. Your doctor will carefully monitor you during your treatment with INCRELEX for development of tumors. If cancerous tumors develop, your doctor will stop your INCRELEX treatment.
  • Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preserved Solution: Serious and fatal adverse reactions can occur in neonates and infants treated with benzyl alcohol-preserved drugs. Use of INCRELEX in infants is not recommended.

The most common adverse reactions include low blood sugar, reactions at the injection site or throughout your body, and enlarged tonsils.

You are encouraged to report negative side effects of prescription drugs by contacting Eton Pharmaceuticals, Inc. at 
1-855-224-0233 or the U.S. Food and Drug Administration (FDA) at www.fda.gov/safety/medwatch or call
1-800-FDA-1088.

Please see full Prescribing Information for more information.

© 2025 Eton Pharmaceuticals. All rights reserved. 02/2025 1887-v2